A recent study published in JAMA Network Open reveals that GLP-1 medications, including popular drugs like Ozempic and Wegovy, may significantly reduce the risk of certain cancers in individuals with type 2 diabetes. The study, conducted by researchers from Case Western Reserve University School of Medicine and the MetroHealth System, analyzed over a decade’s worth of medical records from nearly 1.7 million people.
Key Findings:
- Reduction in Cancer Risk: The study found that individuals treated with GLP-1 drugs were significantly less likely to be diagnosed with 10 out of 13 obesity-associated cancers compared to those treated with insulin. Notably, the risk of gallbladder cancer, meningioma, pancreatic cancer, and hepatocellular carcinoma (a type of liver cancer) was reduced by more than half.
- Broader Implications: The findings suggest a significant reduction in risk for ovarian cancer, colorectal cancer, multiple myeloma, esophageal cancer, endometrial cancer, and kidney cancer among those on GLP-1 treatment.
- Weight and Cancer Connection: Excess weight is known to increase the risk of 13 types of cancer, contributing to about 40% of new cancer diagnoses in the U.S. annually. Overweight individuals often experience long-lasting inflammation and elevated levels of insulin and sex hormones, which can contribute to cancer development.
Comparative Insights:
- Other Treatments: The cancer risk reduction observed with GLP-1 medications compares favorably to the benefits seen with intensive lifestyle changes and metabolic-bariatric surgery, highlighting the potential of these drugs beyond their primary use.
Exceptions and Cautions:
- No Impact on Certain Cancers: The study noted that GLP-1 treatment did not reduce the risk of postmenopausal breast cancer, stomach cancer, or thyroid cancer. In fact, some research indicates potential negative effects on the thyroid.
- Comparison with Metformin: The study found no significant difference in overall cancer diagnosis risk between those treated with GLP-1s and those treated with metformin, although a higher risk of kidney cancer was noted in the GLP-1 group.
Conclusion and Future Directions:
While more research is needed to understand the relationship between weight loss and reduced cancer risk, the study provides preliminary evidence supporting the potential cancer-preventive benefits of GLP-1 receptor agonists in high-risk populations. The authors call for further preclinical and clinical studies to explore these findings in greater detail.
This study underscores the growing understanding of how GLP-1 medications might play a role in cancer prevention, offering hope for new strategies in managing cancer risk among individuals with type 2 diabetes and obesity.
วิสกัส อาหารแมว ชนิดแห้ง แบบเม็ด พ็อกเกต สูตรแมวโต รสปลาทู 3 กก